Melissa Rewolinski - Jul 12, 2023 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Director
Signature
/s/ David C. Hastings as attorney-in-fact for Melissa V. Rewolinski
Stock symbol
ABUS
Transactions as of
Jul 12, 2023
Transactions value $
$0
Form type
4
Date filed
7/13/2023, 04:13 PM
Previous filing
Sep 15, 2022
Next filing
May 24, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $0 +110K $0.00 110K Jul 12, 2023 Common Shares 110K $2.27 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on July 12, 2023, the date of the grant.
F2 The option will vest and become exercisable in three equal annual installments beginning one year from the grant date.